<!DOCTYPE html>
<!-- saved from url=(0024)http://www.blincyto.com/ -->
<html class=" js flexbox flexboxlegacy canvas canvastext webgl no-touch geolocation postmessage websqldatabase indexeddb hashchange history draganddrop websockets rgba hsla multiplebgs backgroundsize borderimage borderradius boxshadow textshadow opacity cssanimations csscolumns cssgradients cssreflections csstransforms csstransforms3d csstransitions fontface generatedcontent video audio localstorage sessionstorage webworkers applicationcache svg inlinesvg smil svgclippaths" lang="en"><!--<![endif]--><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
    
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

    

<title>
    BLINCYTO® (blinatumomab) Health Care Professional Information
</title>

<meta name="WT.site" content="BlincytoHCP">
<meta name="WT.z_bu" content="OBU">
<meta name="WT.cg_n" content="Home">
<meta name="WT.cg_s" content="None">
<meta name="description" content="HCP information for BLINCYTO® (blinatumomab), indicated for the treatment of Ph-negative relapsed or
refractory B-cell precursor acute lymphoblastic leukemia (ALL).">


<script type="text/javascript" src="./BLINCYTO® (blinatumomab) Health Care Professional Information_files/Brightcove_Webtrends_Plugin_V2.0.4.js"></script><script type="text/javascript" src="./BLINCYTO® (blinatumomab) Health Care Professional Information_files/webtrends.yt.js"></script><script type="text/javascript" src="./BLINCYTO® (blinatumomab) Health Care Professional Information_files/webtrends.hm.js"></script><script async="" src="./BLINCYTO® (blinatumomab) Health Care Professional Information_files/webtrends.min.js"></script><script type="text/javascript" src="./BLINCYTO® (blinatumomab) Health Care Professional Information_files/head-default.min.js"></script>


<link type="text/css" rel="stylesheet" href="./BLINCYTO® (blinatumomab) Health Care Professional Information_files/www-blincyto-com.min.css">



<style type="text/css">
    
</style>
<script type="text/javascript">
    "use strict";
    
</script>



    <meta property="og:title" content="BLINCYTO® (blinatumomab) Health Care Professional Information"><meta property="og:description" content="HCP information for BLINCYTO® (blinatumomab), indicated for the treatment of Ph-negative relapsed or
refractory B-cell precursor acute lymphoblastic leukemia (ALL)."><meta property="og:url" content="http://www.blincyto.com/"><meta property="og:image" content="http://www.blincyto.com/~/media/amgen/full/www-blincyto-com/og-image/blincyto-blinatumomab-for-injection.ashx"><meta property="og:site" content="BLINCYTO® (blinatumomab) US HCP Site">
    
<meta class="foundation-data-attribute-namespace"><meta class="foundation-mq-xxlarge"><meta class="foundation-mq-xlarge-only"><meta class="foundation-mq-xlarge"><meta class="foundation-mq-large-only"><meta class="foundation-mq-large"><meta class="foundation-mq-medium-only"><meta class="foundation-mq-medium"><meta class="foundation-mq-small-only"><meta class="foundation-mq-small"><style></style><meta name="WT.z_resdesign" content="Desktop"></head>
<body class="www-blincyto-com Chrome-51-0 en">
    
    
    
    <form method="post" action="http://www.blincyto.com/" id="mainform">
<div class="aspNetHidden">
<input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE" value="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">
</div>

<div class="aspNetHidden">

	<input type="hidden" name="__EVENTVALIDATION" id="__EVENTVALIDATION" value="/wEdAARMwTVp0haFT73xtJhoR7IJwkmOJoOqsgDD44L2ZyUszK2F5uoJNhW57oq7jzCREnxPIo+FFjMupUV05XnSbW0pY2yHnkoaJdFzmUQEbPQHC+GAYpg=">
</div>

        
<div id="hcp-only-modal" class="reveal-modal medium" data-reveal="" data-options="close_on_background_click:false">
    <div class="logo">
        <img src="./BLINCYTO® (blinatumomab) Health Care Professional Information_files/blincyto-blinatumomab-for-injection.ashx" alt="BLINCYTO® (blinatumomab) for injection 35 mcg single-use vial" width="644" height="213">
        <div class="icon-close modal-close"></div>
    </div>
    <div class="modal-bottom">
        <div class="header-text">
            You are now entering the Blincyto.com <br>health care professional website.
        </div>
        <div class="main-text">
            This site is intended for US health care professionals only.
        </div>
        <div class="hcp-link">
            <a id="close-hcp-only-modal" href="http://www.blincyto.com/#">I am a US health care professional</a>
        </div>
        <div class="patient-link">
            <a href="http://pi.amgen.com/united_states/blincyto/blincyto_mg_hcp_english.pdf" target="_blank">I am a patient</a>
        </div>
    </div>
</div>
<div id="leave-site-modal" class="reveal-modal" data-reveal="">
    <a class="close-reveal-modal" aria-label="Close">×</a>
    <div class="logo">
        <img src="./BLINCYTO® (blinatumomab) Health Care Professional Information_files/blincyto-blinatumomab-for-injection.ashx" alt="BLINCYTO® (blinatumomab) for injection 35 mcg single-use vial" width="644" height="213">
    </div>
    <div class="leaving-text">
        <a id="external-link-modal-link" href="http://www.blincyto.com/#" target="_blank">By clicking here, you will be leaving BLINCYTO.com</a>
    </div>
</div>

<div class="indication-tray-widget">
    <div class="row expanded-indication" style="display: none;">
        <div class="column" id="indication-content">
            <div class="title">
                Indication
            </div>
            <div class="x-button">×</div>
            <div class="indication-text">
                BLINCYTO<sup>®</sup> (blinatumomab) is indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials.

            </div>
        </div>
    </div>
    <div class="indication-bar">
        <div class="row">
            <div class="large-10 medium-10 small-8 column bar-text">
                This site is intended for US health care professionals only.
            </div>
            <div class="large-2 medium-2 small-4 column indication-button" id="indication-button">
                Indication
            </div>
        </div>
    </div>
</div>


<div class="universal-header header-bg">
    <ul class="row">
        
                <li class=" "><a href="http://www.blincyto.com/important-safety-information/">Important Safety Information</a></li>
            
                <li class=" "><a class="external-link" target="_blank" href="http://pi.amgen.com/united_states/blincyto/blincyto_pi_hcp_english.pdf" onclick="callFloodlightDtp(&#39;blinc0&#39;,&#39;amg_b00), callFloodlight(&#39;bphase2&#39;,&#39;blin02&#39;)" data-tooltip="" aria-haspopup="true" data-width="140" data-selector="tooltip-ir59dbab0" aria-describedby="tooltip-ir59dbab0" title="">Full Prescribing Information</a></li>
            
                <li class="  desktop-only"><a class="external-link" target="_blank" href="http://www.amgenmedinfo.com/" onclick="callFloodlight(&#39;bphase2&#39;,&#39;blin03&#39;)" data-tooltip="" aria-haspopup="true" data-width="140" data-selector="tooltip-ir59dbab1" aria-describedby="tooltip-ir59dbab1" title="">Medical Information</a></li>
            
                <li class="  desktop-only"><a class="external-link" target="_blank" href="http://www.blincytorems.com/" onclick="callFloodlight(&#39;bphase2&#39;,&#39;blin04&#39;)" data-tooltip="" aria-haspopup="true" data-width="140" data-selector="tooltip-ir59dbab2" aria-describedby="tooltip-ir59dbab2" title="">BLINCYTO<sup>®</sup> REMS</a></li>
            
                <li class="  desktop-only"><a class="external-link" target="_blank" href="http://pi.amgen.com/united_states/blincyto/blincyto_mg_hcp_english.pdf" onclick="callFloodlightDtp(&#39;blinc0&#39;,&#39;amg_b000&#39;), callFloodlight(&#39;bphase2&#39;,&#39;blin05&#39;)" data-tooltip="" aria-haspopup="true" data-width="140" data-selector="tooltip-ir59dbab3" aria-describedby="tooltip-ir59dbab3" title="">Medication Guide</a></li>
            
    </ul>
</div><input type="hidden" name="header_3$TimeUntilShown" id="TimeUntilShown" value="2">
<input type="hidden" name="header_3$TimeUntilHidden" id="TimeUntilHidden" value="24">

<div class="hero-container" data-uuid="interchange-ir59dba20" style="background-image: url('/media/amgen/full/www-blincyto-com/hero-backgrounds/images/hero-header-home-desktop.jpg');">
    
    <video poster="/static/blincyto/img/transparent.png" loop="">
        
                <source src="http://www.blincyto.com/~/media/AD7314E7F30948E5883A38FDC507FA03" type="video/mp4">
            
    </video>
    <div class="mobile-hamburger-area show-for-small-only">
        <div class="mobile-btn">
            <div></div>
            <div></div>
            <div></div>
        </div>
    </div>
    <div class="row">
        <div class="large-4 medium-7 column">
            <div class="left-box">
                <div class="mobile-logo-image show-for-small-only ">
                    <a href="http://www.blincyto.com/"><img src="./BLINCYTO® (blinatumomab) Health Care Professional Information_files/blincyto-blinatumomab-for-injection.ashx" alt="BLINCYTO® (blinatumomab) for injection 35 mcg single-use vial" width="644" height="213"></a>
                </div>
                <div class="logo-image show-for-medium-up"> 
                    <a href="http://www.blincyto.com/"><img src="./BLINCYTO® (blinatumomab) Health Care Professional Information_files/blincyto-blinatumomab-for-injection.ashx" alt="BLINCYTO® (blinatumomab) for injection 35 mcg single-use vial" width="644" height="213"></a>
                </div>
                <div class="left-text bordered">
                    For Ph-negative relapsed or refractory (R/R)<br>B-cell precursor acute lymphoblastic leukemia (ALL)
                </div>
            </div>
        </div>
        <div class="large-4 medium-4 column right-box-row">
            <div class="right-box" style="opacity: 0;">
                <div class="header-text">
                    HARNESS THE POWER OF A SINGLE-AGENT IMMUNOTHERAPY
                </div>
                <div class="center-text">
                    <span><b>41.6%</b></span> of evaluable patients achieved a <b>complete remission (CR) or complete remission with partial hematological recovery (CRh*)</b> during the first 2 treatment cycles <span class="nobreak">(n=77/185; 95% CI: 34.4-49.1)<sup>1</sup></span>
                </div>
                <div class="box-link">
                    <a href="http://www.blincyto.com/clinical-data/"><span class="mobile-only">Click here for information about <br>BLINCYTO's Pivotal Trial</span><span class="dkt-only">Learn more about the Pivotal Trial</span><i class="fa fa-angle-right"></i></a>
                </div>
                <div class="bottom-text">
                    BREAKTHROUGH THERAPY<br>DESIGNATION BY THE FDA<sup>2</sup>
                </div>
            </div>
        </div>
    </div>
</div>
<div class="mobile-nav-wrapper" style="display: none;" id="mobileNav">
   <ul class="mobile-nav">
        
                <li class="home-link  active"><a href="http://www.blincyto.com/">HOME</a></li>
            
                <li class="nav-link "><span class="icon icon-chevron-right"></span><a href="http://www.blincyto.com/blincyto-blinatumomab/">About BLINCYTO<sup>®</sup></a></li>
            
                <li class="nav-link "><span class="icon icon-chevron-right"></span><a href="http://www.blincyto.com/clinical-data/">Clinical Data</a></li>
            
                <li class="nav-link "><span class="icon icon-chevron-right"></span><a href="http://www.blincyto.com/safety-adverse-reactions/safety-adverse-reactions/">Safety</a></li>
            
                <li class="nav-link "><span class="icon icon-chevron-right"></span><a href="http://www.blincyto.com/dosage/">Dosage &amp; Administration</a></li>
            
                <li class="nav-link "><span class="icon icon-chevron-right"></span><a href="http://www.blincyto.com/preparation/">Preparation</a></li>
            
                <li class="nav-link "><span class="icon icon-chevron-right"></span><a href="http://www.blincyto.com/support-materials/">Support Materials</a></li>
            
        
                <li class="uh-link"><a class="external-link" href="http://www.amgenmedinfo.com/" target="_blank" data-tooltip="" aria-haspopup="true" data-width="140" data-selector="tooltip-ir59dbab4" aria-describedby="tooltip-ir59dbab4" title="">Medical Information</a></li>
            
                <li class="uh-link"><a class="external-link" href="http://www.blincytorems.com/" target="_blank" data-tooltip="" aria-haspopup="true" data-width="140" data-selector="tooltip-ir59dbab5" aria-describedby="tooltip-ir59dbab5" title="">BLINCYTO<sup>®</sup> REMS</a></li>
            
                <li class="uh-link"><a class="external-link" href="http://pi.amgen.com/united_states/blincyto/blincyto_mg_hcp_english.pdf" target="_blank" data-tooltip="" aria-haspopup="true" data-width="140" data-selector="tooltip-ir59dbab6" aria-describedby="tooltip-ir59dbab6" title="">Medication Guide</a></li>
            
    </ul>
</div>

<div class="main-nav show-for-medium-up">
    <ul class="row desktop-nav ">
        
                <li class=" "><a href="http://www.blincyto.com/blincyto-blinatumomab/">About BLINCYTO<sup>®</sup></a></li>
            
                <li class=" "><a href="http://www.blincyto.com/clinical-data/">Clinical Data</a></li>
            
                <li class=" "><a href="http://www.blincyto.com/safety-adverse-reactions/safety-adverse-reactions/">Safety</a></li>
            
                <li class=" "><a href="http://www.blincyto.com/dosage/">Dosage &amp; Administration</a></li>
            
                <li class=" "><a href="http://www.blincyto.com/preparation/">Preparation</a></li>
            
                <li class=" "><a href="http://www.blincyto.com/support-materials/">Support Materials</a></li>
            
    </ul>
</div>

        

<div class="row homepage-middle">
    <div class="column small-12 medium-7">
        <div class="horizontal-image-link-callouts">
            
                  <a href="http://www.blincyto.com/support-materials/blincyto-tools/#for-nurses" target="" class=" callout-link">
                    </a><div class="callout item-0"><a href="http://www.blincyto.com/support-materials/blincyto-tools/#for-nurses" target="" class=" callout-link">
                        <div class="image">
                            <img src="./BLINCYTO® (blinatumomab) Health Care Professional Information_files/blincyto-blinatumomab-nurses-guide.ashx" alt="BLINCYTO® (blinatumomab) Guide for Nurses" width="110" height="70">
                        </div>

                        <span class="title">
                            Administering BLINCYTO<sup>®</sup>
                        </span>
                        <span class="subtitle">
                            View nurse guide</span>
                        <span class="icon icon-chevron-right"></span>
                        </a>
                    </div>
                
                  <a href="http://www.blincyto.com/preparation/admixing/#admix-video" target="" class=" callout-link">
                    </a><div class="callout item-1"><a href="http://www.blincyto.com/preparation/admixing/#admix-video" target="" class=" callout-link">
                        <div class="image">
                            <img src="./BLINCYTO® (blinatumomab) Health Care Professional Information_files/admix.ashx" alt="Admixing BLINCYTO® (blinatumomab) Video" width="1280" height="720">
                        </div>

                        <span class="title">
                            Preparing BLINCYTO<sup>®</sup>
                        </span>
                        <span class="subtitle">
                            WATCH ADMIX VIDEOS</span>
                        <span class="icon icon-chevron-right"></span>
                        </a>
                    </div>
                
                  <a href="http://www.blincyto.com/support-materials/blincyto-tools/#supporting-your-patients" target="" class=" callout-link">
                    </a><div class="callout item-2"><a href="http://www.blincyto.com/support-materials/blincyto-tools/#supporting-your-patients" target="" class=" callout-link">
                        <div class="image">
                            
                        </div>

                        <span class="title">
                            Supporting Your Patients
                        </span>
                        <span class="subtitle">
                            LEARN MORE</span>
                        <span class="icon icon-chevron-right"></span>
                        </a>
                    </div>
                
        </div>
    </div>
    <div class="column small-12 medium-5">
        <div class="horizontal-background-image-callouts">
            <div class="horizontal-background-image-callouts">
                
                        <div class="callout item-0">
                            <div class="link">
                                <a href="http://www.amgenmedinfo.com/" target="_blank" class="external-link" onclick="callFloodlight(&#39;bphase2&#39;,&#39;blin06&#39;)" data-tooltip="" aria-haspopup="true" data-width="140" data-selector="tooltip-ir59dbab7" aria-describedby="tooltip-ir59dbab7" title="">
                                    <span class="link-header">HAVE QUESTIONS?
                                        
                                    </span>
                                    <br>
                                    <span class="link-subheader">CONTACT AMGEN MEDICAL INFORMATION </span>
                                </a>
                            </div>
                        </div>
                    
                        <div class="callout item-1">
                            <div class="link">
                                <a href="http://www.blincyto.com/blincyto-blinatumomab/patient-profiles/" target="" class="">
                                    <span class="link-header with-image">IDENTIFYING PATIENTS
                                        <img src="./BLINCYTO® (blinatumomab) Health Care Professional Information_files/home-patient-profiles.ashx" alt="Identifying Patients for BLINCYTO® Therapy" width="162" height="88">
                                    </span>
                                    <br>
                                    <span class="link-subheader">SEE PATIENT PROFILES</span>
                                </a>
                            </div>
                        </div>
                    
            </div>
        </div>
    </div>
</div>


        

<div class="safety-footer clearfix">
    <div class="safety-footer-full">
        <div class="row">
            <div class="column">       
            <div class="isi-header no-margin-tray isi-subhead-subtile">IMPORTANT SAFETY INFORMATION</div>
<p class="no-margin-tray"><strong>WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES</strong></p>
<ul style="font-weight: bold;">
    <li class="no-margin-tray">Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO<sup>®</sup> (blinatumomab). Interrupt or discontinue BLINCYTO<sup>®</sup> as recommended.</li>
    <li>Neurological toxicities, which may be severe, life-threatening or fatal, occurred in patients receiving BLINCYTO<sup>®</sup>. Interrupt or discontinue BLINCYTO<sup>®</sup> as recommended.</li>
</ul>
<div class="isi-subhead">Contraindications</div>
<p>BLINCYTO<sup>®</sup> is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation.</p>
<div class="isi-subhead">Warnings and Precautions</div>
<ul>
    <li>Cytokine Release Syndrome (CRS): Life-threatening or fatal CRS occurred in patients receiving BLINCYTO<sup>®</sup>. Infusion reactions have occurred and may be clinically indistinguishable from manifestations of CRS. Closely monitor patients for signs and symptoms of serious events such as pyrexia, headache, nausea, asthenia, hypotension, increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), increased total bilirubin (TBILI), disseminated intravascular coagulation (DIC), capillary leak syndrome (CLS), and hemophagocytic lymphohistiocytosis / macrophage activation syndrome (HLH/MAS). Interrupt or discontinue BLINCYTO<sup>®</sup> as outlined in the Prescribing Information (PI).</li>
    <li>Neurological Toxicities: Approximately 50% of patients receiving BLINCYTO<sup>®</sup> in clinical trials experienced neurological toxicities. Severe, life-threatening, or fatal neurological toxicities occurred in approximately 15% of patients, including encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and
    disorientation, and coordination and balance disorders. The median time to onset of any neurological toxicity was 7 days. Monitor patients for signs or symptoms and interrupt or discontinue BLINCYTO<sup>®</sup> as outlined in the PI.</li>
    <li>Infections: Approximately 25% of patients receiving BLINCYTO<sup>®</sup> experienced serious infections, some of which were life-threatening or fatal. Administer prophylactic antibiotics and employ surveillance testing as appropriate during treatment. Monitor patients for signs or symptoms of infection and treat appropriately, including interruption or discontinuation of BLINCYTO<sup>®</sup> as needed.</li>
    <li>Tumor Lysis Syndrome (TLS): Life-threatening or fatal TLS has been observed. Preventive measures, including pretreatment nontoxic cytoreduction and on treatment hydration, should be used during BLINCYTO<sup>®</sup> treatment. Monitor patients for signs and symptoms of TLS and interrupt or discontinue BLINCYTO<sup>®</sup> as needed to manage
    these events.</li>
    <li>Neutropenia and Febrile Neutropenia, including life-threatening cases, have been observed. Monitor appropriate laboratory parameters during BLINCYTO<sup>®</sup> infusion and interrupt BLINCYTO<sup>®</sup> if prolonged neutropenia occurs.</li>
    <li>Effects on Ability to Drive and Use Machines: Due to the possibility of neurological events, including seizures, patients receiving BLINCYTO<sup>®</sup> are at risk for loss of consciousness, and should be advised against driving and engaging in hazardous occupations or activities such as operating heavy or potentially dangerous machinery while BLINCYTO<sup>®</sup> is being administered.</li>
    <li>Elevated Liver Enzymes: Transient elevations in liver enzymes have been associated with BLINCYTO<sup>®</sup> treatment. The majority of these events were observed in the setting of CRS. The median time to onset was 15 days. Grade 3 or greater elevations in liver enzymes occurred in 6% of patients outside the setting of CRS and resulted in treatment discontinuation in less than 1% of patients. Monitor ALT, AST, gamma-glutamyl transferase (GGT), and TBILI prior to the start of and during BLINCYTO<sup>®</sup> treatment. BLINCYTO<sup>®</sup> treatment should be interrupted if transaminases rise to &gt; 5 times the upper limit of normal (ULN) or if TBILI rises to &gt; 3 times ULN.</li>
    <li>Leukoencephalopathy: Although the clinical significance is unknown, cranial magnetic resonance imaging (MRI) changes showing leukoencephalopathy have been observed in patients receiving BLINCYTO<sup>®</sup>, especially in patients previously treated with cranial irradiation and anti-leukemic chemotherapy.</li>
    <li>Preparation and administration errors have occurred with BLINCYTO<sup>®</sup> treatment. Follow instructions for preparation (including admixing) and administration in the PI strictly to minimize medication errors (including underdose and overdose).</li>
</ul>
<p>
</p>
<div class="isi-subhead">Adverse Reactions</div>
<ul>
    <li>The most commonly reported adverse reactions (≥ 20%) in clinical trials were pyrexia (62%), headache (36%), peripheral edema (25%), febrile neutropenia (25%), nausea (25%), hypokalemia (23%), rash (21%), tremor (20%), diarrhea (20%) and constipation (20%).</li>
    <li>Serious adverse reactions were reported in 65% of patients. The most common serious adverse reactions (≥ 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion, <em>Staphylococcal</em> bacteremia, and headache.</li>
</ul>
<p>
</p>
<div class="isi-subhead">Dosage and Administration Guidelines</div>
<ul>
    <li>BLINCYTO<sup>®</sup> is administered as a continuous intravenous infusion at a constant flow rate using an infusion pump which should be programmable, lockable, non-elastomeric, and have an alarm.</li>
    <li>It is very important that the instructions for preparation (including admixing) and administration provided in the full Prescribing Information are strictly followed to minimize medication errors (including underdose and overdose).</li>
</ul>
<p>Please see <a href="http://pi.amgen.com/united_states/blincyto/blincyto_pi_hcp_english.pdf" target="_blank" class="external-link underlined" data-tooltip="" aria-haspopup="true" data-width="140" data-selector="tooltip-ir59dbab8" aria-describedby="tooltip-ir59dbab8" title="">full Prescribing Information</a>, including <strong>Boxed WARNINGS</strong> and <a href="http://pi.amgen.com/united_states/blincyto/blincyto_mg_hcp_english.pdf" target="_blank" class="external-link underlined" data-tooltip="" aria-haspopup="true" data-width="140" data-selector="tooltip-ir59dbab9" aria-describedby="tooltip-ir59dbab9" title="">Medication Guide</a>, for BLINCYTO<sup>®</sup>.</p>
<div class="isi-subhead isi-subhead-subtile">INDICATION</div>
<p>BLINCYTO<sup>®</sup> is indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).</p>
<p>This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials.</p>
            </div> 
        </div>
    </div>
    <div class="safety-footer-tray" style="visibility: visible;">
        <div class="row">
            <div class="column">    
                
                <a class="expand-button right" href="http://www.blincyto.com/#"><i class="icon-chevron-up hidden-dkt"></i><span class="see-more hidden-mb">SEE MORE</span></a>
                <a class="collapse-button icon-chevron-down right" href="http://www.blincyto.com/#" style="display:none;"></a>
                <div class="isi-header no-margin-tray isi-subhead-subtile">IMPORTANT SAFETY INFORMATION</div>
<p class="no-margin-tray"><strong>WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES</strong></p>
<ul style="font-weight: bold;">
    <li class="no-margin-tray">Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO<sup>®</sup> (blinatumomab). Interrupt or discontinue BLINCYTO<sup>®</sup> as recommended.</li>
    <li>Neurological toxicities, which may be severe, life-threatening or fatal, occurred in patients receiving BLINCYTO<sup>®</sup>. Interrupt or discontinue BLINCYTO<sup>®</sup> as recommended.</li>
</ul>
<div class="isi-subhead">Contraindications</div>
<p>BLINCYTO<sup>®</sup> is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation.</p>
<div class="isi-subhead">Warnings and Precautions</div>
<ul>
    <li>Cytokine Release Syndrome (CRS): Life-threatening or fatal CRS occurred in patients receiving BLINCYTO<sup>®</sup>. Infusion reactions have occurred and may be clinically indistinguishable from manifestations of CRS. Closely monitor patients for signs and symptoms of serious events such as pyrexia, headache, nausea, asthenia, hypotension, increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), increased total bilirubin (TBILI), disseminated intravascular coagulation (DIC), capillary leak syndrome (CLS), and hemophagocytic lymphohistiocytosis / macrophage activation syndrome (HLH/MAS). Interrupt or discontinue BLINCYTO<sup>®</sup> as outlined in the Prescribing Information (PI).</li>
    <li>Neurological Toxicities: Approximately 50% of patients receiving BLINCYTO<sup>®</sup> in clinical trials experienced neurological toxicities. Severe, life-threatening, or fatal neurological toxicities occurred in approximately 15% of patients, including encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and
    disorientation, and coordination and balance disorders. The median time to onset of any neurological toxicity was 7 days. Monitor patients for signs or symptoms and interrupt or discontinue BLINCYTO<sup>®</sup> as outlined in the PI.</li>
    <li>Infections: Approximately 25% of patients receiving BLINCYTO<sup>®</sup> experienced serious infections, some of which were life-threatening or fatal. Administer prophylactic antibiotics and employ surveillance testing as appropriate during treatment. Monitor patients for signs or symptoms of infection and treat appropriately, including interruption or discontinuation of BLINCYTO<sup>®</sup> as needed.</li>
    <li>Tumor Lysis Syndrome (TLS): Life-threatening or fatal TLS has been observed. Preventive measures, including pretreatment nontoxic cytoreduction and on treatment hydration, should be used during BLINCYTO<sup>®</sup> treatment. Monitor patients for signs and symptoms of TLS and interrupt or discontinue BLINCYTO<sup>®</sup> as needed to manage
    these events.</li>
    <li>Neutropenia and Febrile Neutropenia, including life-threatening cases, have been observed. Monitor appropriate laboratory parameters during BLINCYTO<sup>®</sup> infusion and interrupt BLINCYTO<sup>®</sup> if prolonged neutropenia occurs.</li>
    <li>Effects on Ability to Drive and Use Machines: Due to the possibility of neurological events, including seizures, patients receiving BLINCYTO<sup>®</sup> are at risk for loss of consciousness, and should be advised against driving and engaging in hazardous occupations or activities such as operating heavy or potentially dangerous machinery while BLINCYTO<sup>®</sup> is being administered.</li>
    <li>Elevated Liver Enzymes: Transient elevations in liver enzymes have been associated with BLINCYTO<sup>®</sup> treatment. The majority of these events were observed in the setting of CRS. The median time to onset was 15 days. Grade 3 or greater elevations in liver enzymes occurred in 6% of patients outside the setting of CRS and resulted in treatment discontinuation in less than 1% of patients. Monitor ALT, AST, gamma-glutamyl transferase (GGT), and TBILI prior to the start of and during BLINCYTO<sup>®</sup> treatment. BLINCYTO<sup>®</sup> treatment should be interrupted if transaminases rise to &gt; 5 times the upper limit of normal (ULN) or if TBILI rises to &gt; 3 times ULN.</li>
    <li>Leukoencephalopathy: Although the clinical significance is unknown, cranial magnetic resonance imaging (MRI) changes showing leukoencephalopathy have been observed in patients receiving BLINCYTO<sup>®</sup>, especially in patients previously treated with cranial irradiation and anti-leukemic chemotherapy.</li>
    <li>Preparation and administration errors have occurred with BLINCYTO<sup>®</sup> treatment. Follow instructions for preparation (including admixing) and administration in the PI strictly to minimize medication errors (including underdose and overdose).</li>
</ul>
<p>
</p>
<div class="isi-subhead">Adverse Reactions</div>
<ul>
    <li>The most commonly reported adverse reactions (≥ 20%) in clinical trials were pyrexia (62%), headache (36%), peripheral edema (25%), febrile neutropenia (25%), nausea (25%), hypokalemia (23%), rash (21%), tremor (20%), diarrhea (20%) and constipation (20%).</li>
    <li>Serious adverse reactions were reported in 65% of patients. The most common serious adverse reactions (≥ 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion, <em>Staphylococcal</em> bacteremia, and headache.</li>
</ul>
<p>
</p>
<div class="isi-subhead">Dosage and Administration Guidelines</div>
<ul>
    <li>BLINCYTO<sup>®</sup> is administered as a continuous intravenous infusion at a constant flow rate using an infusion pump which should be programmable, lockable, non-elastomeric, and have an alarm.</li>
    <li>It is very important that the instructions for preparation (including admixing) and administration provided in the full Prescribing Information are strictly followed to minimize medication errors (including underdose and overdose).</li>
</ul>
<p>Please see <a href="http://pi.amgen.com/united_states/blincyto/blincyto_pi_hcp_english.pdf" target="_blank" class="external-link underlined" data-tooltip="" aria-haspopup="true" data-width="140" data-selector="tooltip-ir59dbaba" aria-describedby="tooltip-ir59dbaba" title="">full Prescribing Information</a>, including <strong>Boxed WARNINGS</strong> and <a href="http://pi.amgen.com/united_states/blincyto/blincyto_mg_hcp_english.pdf" target="_blank" class="external-link underlined" data-tooltip="" aria-haspopup="true" data-width="140" data-selector="tooltip-ir59dbabb" aria-describedby="tooltip-ir59dbabb" title="">Medication Guide</a>, for BLINCYTO<sup>®</sup>.</p>
<div class="isi-subhead isi-subhead-subtile">INDICATION</div>
<p>BLINCYTO<sup>®</sup> is indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).</p>
<p>This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials.</p>
            </div>
        </div>
    </div>
</div>
<div class="references">
    <div class="row">
        <div class="column">
        CR = complete remission, defined as ≤ 5% of blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts (platelets &gt; 100,000/microliter and absolute neutrophil counts [ANC] &gt; 1,000/microliter).<sup>1</sup>
<br><br>

CRh* = complete remission with partial hematological recovery, defined as ≤ 5% of blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts (platelets &gt; 50,000 /microliter and ANC &gt; 500/microliter).<sup>1</sup>
<br><br>

<b>References:</b> <ol><li>BLINCYTO<sup>®</sup> (blinatumomab) Prescribing Information, Amgen.</li><li>Data on file, Amgen; [FDA letter]; 2014.</li></ol>
            </div>
    </div>
</div>
<div class="footer clearfix">
    <div class="row">
        <ul class="footer-links large-3 column">
            
                   <li class="footer-link item-0">
                       <a href="http://www.blincyto.com/sitemap/">Sitemap</a>
                   </li>
                
                   <li class="footer-link item-1">
                       <a class="external-link" target="_blank" href="http://wwwext.amgen.com/privacy/use.html" onclick="callFloodlight(&#39;bphase2&#39;,&#39;blin08&#39;)" data-tooltip="" aria-haspopup="true" data-width="140" data-selector="tooltip-ir59dbabc" aria-describedby="tooltip-ir59dbabc" title="">Terms of Use</a>
                   </li>
                
                   <li class="footer-link item-2">
                       <a class="external-link" target="_blank" href="http://wwwext.amgen.com/privacy/statement.html" onclick="callFloodlight(&#39;bphase2&#39;,&#39;blin09&#39;)" data-tooltip="" aria-haspopup="true" data-width="140" data-selector="tooltip-ir59dbabd" aria-describedby="tooltip-ir59dbabd" title="">Privacy Statement</a>
                   </li>
                
                   <li class="footer-link item-3">
                       <a class="external-link" target="_blank" href="http://wwwext.amgen.com/contact_us/amgen_contact.htm" onclick="callFloodlight(&#39;bphase2&#39;,&#39;blin07&#39;)" data-tooltip="" aria-haspopup="true" data-width="140" data-selector="tooltip-ir59dbabe" aria-describedby="tooltip-ir59dbabe" title="">Contact Us</a>
                   </li>
                
        </ul>
        <div class="logos large-2 column">
            <a href="http://www.amgenoncology.com/" onclick="callFloodlight(&#39;bphase2&#39;,&#39;blin10&#39;)" class="external-link" target="_blank" data-tooltip="" aria-haspopup="true" data-width="140" data-selector="tooltip-ir59dbabf" aria-describedby="tooltip-ir59dbabf" title="">
                <img src="./BLINCYTO® (blinatumomab) Health Care Professional Information_files/amgen.ashx" alt="Amgen®" width="120" height="35">
            </a>
            <a href="http://www.onyx.com/" onclick="callFloodlight(&#39;bphase2&#39;,&#39;blin11&#39;)" class="external-link" target="_blank" data-tooltip="" aria-haspopup="true" data-width="140" data-selector="tooltip-ir59dbabg" aria-describedby="tooltip-ir59dbabg" title="">
                
            </a>
        </div>
        <div class="footer-text large-7 column">
            <p>This site is intended to be used by health care professionals for informational purposes only and is not intended to offer medical advice or to be a substitute for seeking medical care.</p>
	
<p>BLINCYTO<sup>®</sup> is a registered trademark of Amgen Inc.<br>
© 2016 Amgen Inc. All rights reserved. </p>
            <p>USA-103-106579 4/16</p>
        </div>
    </div>
</div>

    <script language="javascript" type="text/javascript" src="./BLINCYTO® (blinatumomab) Health Care Professional Information_files/jquery.js"></script>
<script language="javascript" type="text/javascript" src="./BLINCYTO® (blinatumomab) Health Care Professional Information_files/jquery.fancybox-1.3.4.pack.js"></script>
<script language="javascript" type="text/javascript" src="./BLINCYTO® (blinatumomab) Health Care Professional Information_files/mediaframework.js"></script>
<link rel="Stylesheet" href="./BLINCYTO® (blinatumomab) Health Care Professional Information_files/jquery.fancybox-1.3.4.css">
<input type="hidden" name="MediaFramework_ItemId" id="MediaFramework_ItemId" value="30F337B845DD4F13B58073C0AC09387D"></form>
<script type="text/javascript" src="./BLINCYTO® (blinatumomab) Health Care Professional Information_files/body-www-blincyto-com.min.js"></script><span data-selector="tooltip-ir59dbab0" id="tooltip-ir59dbab0" class="tooltip tip-override" role="tooltip" style="display: none; width: 100%; top: 72px; bottom: auto; left: 12.5px; right: auto; visibility: visible;">By clicking here, you will be leaving BLINCYTO.com<span class="nub" style="top: -16px; bottom: auto; left: 304px; right: auto;"></span></span><span data-selector="tooltip-ir59dbab1" id="tooltip-ir59dbab1" class="tooltip" role="tooltip">By clicking here, you will be leaving BLINCYTO.com<span class="nub"></span></span><span data-selector="tooltip-ir59dbab2" id="tooltip-ir59dbab2" class="tooltip" role="tooltip">By clicking here, you will be leaving BLINCYTO.com<span class="nub"></span></span><span data-selector="tooltip-ir59dbab3" id="tooltip-ir59dbab3" class="tooltip" role="tooltip">By clicking here, you will be leaving BLINCYTO.com<span class="nub"></span></span><span data-selector="tooltip-ir59dbab4" id="tooltip-ir59dbab4" class="tooltip tip-override" role="tooltip" style="display: none; width: 100%; top: 469px; bottom: auto; left: 12.5px; right: auto; visibility: visible;">By clicking here, you will be leaving BLINCYTO.com<span class="nub" style="top: -16px; bottom: auto; left: 25px; right: auto;"></span></span><span data-selector="tooltip-ir59dbab5" id="tooltip-ir59dbab5" class="tooltip tip-override" role="tooltip" style="display: none; width: 100%; top: 508px; bottom: auto; left: 12.5px; right: auto; visibility: visible;">By clicking here, you will be leaving BLINCYTO.com<span class="nub" style="top: -16px; bottom: auto; left: 25px; right: auto;"></span></span><span data-selector="tooltip-ir59dbab6" id="tooltip-ir59dbab6" class="tooltip" role="tooltip">By clicking here, you will be leaving BLINCYTO.com<span class="nub"></span></span><span data-selector="tooltip-ir59dbab7" id="tooltip-ir59dbab7" class="tooltip" role="tooltip" style="display: none; width: 140px; top: 727px; bottom: auto; left: 1049.84px; right: auto; visibility: visible;">By clicking here, you will be leaving BLINCYTO.com<span class="nub"></span></span><span data-selector="tooltip-ir59dbab8" id="tooltip-ir59dbab8" class="tooltip" role="tooltip">By clicking here, you will be leaving BLINCYTO.com<span class="nub"></span></span><span data-selector="tooltip-ir59dbab9" id="tooltip-ir59dbab9" class="tooltip" role="tooltip">By clicking here, you will be leaving BLINCYTO.com<span class="nub"></span></span><span data-selector="tooltip-ir59dbaba" id="tooltip-ir59dbaba" class="tooltip" role="tooltip">By clicking here, you will be leaving BLINCYTO.com<span class="nub"></span></span><span data-selector="tooltip-ir59dbabb" id="tooltip-ir59dbabb" class="tooltip" role="tooltip">By clicking here, you will be leaving BLINCYTO.com<span class="nub"></span></span><span data-selector="tooltip-ir59dbabc" id="tooltip-ir59dbabc" class="tooltip" role="tooltip">By clicking here, you will be leaving BLINCYTO.com<span class="nub"></span></span><span data-selector="tooltip-ir59dbabd" id="tooltip-ir59dbabd" class="tooltip" role="tooltip">By clicking here, you will be leaving BLINCYTO.com<span class="nub"></span></span><span data-selector="tooltip-ir59dbabe" id="tooltip-ir59dbabe" class="tooltip" role="tooltip">By clicking here, you will be leaving BLINCYTO.com<span class="nub"></span></span><span data-selector="tooltip-ir59dbabf" id="tooltip-ir59dbabf" class="tooltip" role="tooltip">By clicking here, you will be leaving BLINCYTO.com<span class="nub"></span></span><span data-selector="tooltip-ir59dbabg" id="tooltip-ir59dbabg" class="tooltip" role="tooltip">By clicking here, you will be leaving BLINCYTO.com<span class="nub"></span></span>
    
    <script type="text/javascript">
        "use strict";
        
    </script>

    <script type="text/javascript">
        //alert("I am an alert box!");
        document.getElementById('indication-button').onclick = function()
       {
           //alert($('#indication-content').height());
           var element = document.getElementById('mobileNav'),
           style = window.getComputedStyle(element),
           top = style.getPropertyValue('top');
           alert(top);
           //document.getElementById("mobileNav").style.top = document.getElementById('mobileNav').style.top + document.getElementById("myImg").style.height;
       }
    </script>
<!--
Start of DoubleClick Floodlight Tag: Please do not remove
Activity name of this tag: Blincyto Phase 2 - Blincyto Home Page
URL of the webpage where the tag is expected to be placed: https://blincyto-com.obu.uat.amgenwebservices.com/
This tag must be placed between the <body> and </body> tags, as close as possible to the opening tag.
Creation Date: 06/18/2015
-->
<script type="text/javascript">
var axel = Math.random() + "";
var a = axel * 10000000000000;
document.write('<iframe src="https://4308149.fls.doubleclick.net/activityi;src=4308149;type=bphase2;cat=blin01;ord=' + a + '?" width="1" height="1" frameborder="0" style="display:none"></iframe>');
</script><iframe src="./BLINCYTO® (blinatumomab) Health Care Professional Information_files/activityi.html" width="1" height="1" frameborder="0" style="display:none"></iframe>
<noscript>
&lt;iframe src="https://4308149.fls.doubleclick.net/activityi;src=4308149;type=bphase2;cat=blin01;ord=1?" width="1" height="1" frameborder="0" style="display:none"&gt;&lt;/iframe&gt;
</noscript>
<!-- End of DoubleClick Floodlight Tag: Please do not remove -->

<!--
Start of DoubleClick Floodlight Tag: Please do not remove
Activity name of this tag: AMG_Blin_Home Page
URL of the webpage where the tag is expected to be placed: http://blincytoqa.nexio.com/
This tag must be placed between the <body> and </body> tags, as close as possible to the opening tag.
Creation Date: 05/12/2016
-->
<script type="text/javascript">
var axel = Math.random() + "";
var a = axel * 10000000000000;
document.write('<iframe src="https://4315853.fls.doubleclick.net/activityi;src=4315853;type=blinc0;cat=amg_b0;dc_lat=;dc_rdid=;tag_for_child_directed_treatment=;ord=1;num=' + a + '?" width="1" height="1" frameborder="0" style="display:none"></iframe>');
</script><iframe src="./BLINCYTO® (blinatumomab) Health Care Professional Information_files/activityi(1).html" width="1" height="1" frameborder="0" style="display:none"></iframe>
<noscript>
&lt;iframe src="https://4315853.fls.doubleclick.net/activityi;src=4315853;type=blinc0;cat=amg_b0;dc_lat=;dc_rdid=;tag_for_child_directed_treatment=;ord=1;num=1?" width="1" height="1" frameborder="0" style="display:none"&gt;&lt;/iframe&gt;
</noscript>
<!-- End of DoubleClick Floodlight Tag: Please do not remove -->



<div id="fancybox-tmp"></div><div id="fancybox-loading"><div></div></div><div id="fancybox-overlay"></div><div id="fancybox-wrap"><div id="fancybox-outer"><div class="fancybox-bg" id="fancybox-bg-n"></div><div class="fancybox-bg" id="fancybox-bg-ne"></div><div class="fancybox-bg" id="fancybox-bg-e"></div><div class="fancybox-bg" id="fancybox-bg-se"></div><div class="fancybox-bg" id="fancybox-bg-s"></div><div class="fancybox-bg" id="fancybox-bg-sw"></div><div class="fancybox-bg" id="fancybox-bg-w"></div><div class="fancybox-bg" id="fancybox-bg-nw"></div><div id="fancybox-content"></div><a id="fancybox-close"></a><div id="fancybox-title"></div><a href="javascript:;" id="fancybox-left"><span class="fancy-ico" id="fancybox-left-ico"></span></a><a href="javascript:;" id="fancybox-right"><span class="fancy-ico" id="fancybox-right-ico"></span></a></div></div><div id="viewPortSize" class="bottom_left" style="color: rgb(0, 0, 0); font-size: 20px; display: block; background-color: rgb(255, 100, 251);">Inner: 1920 x 935<br>Outer: 1920 x 1040</div><div id="window-resizer-tooltip" style="display: block;"><a href="http://www.blincyto.com/#" title="Edit settings"></a><span class="tooltipTitle">Window size: </span><span class="tooltipWidth" id="winWidth">1920</span> x <span class="tooltipHeight" id="winHeight">1040</span><br><span class="tooltipTitle">Viewport size: </span><span class="tooltipWidth" id="vpWidth">1920</span> x <span class="tooltipHeight" id="vpHeight">935</span></div></body></html>